Global Oncology Biosimilars Market by Product Type (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Erythropoietin, Interferons), by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by End-Use Industry (Hospitals, Clinics, Research Institutes); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Oncology Biosimilars Market was valued at USD 7.6 Billion in 2024-e and will surpass USD 17.2 Billion by 2030; growing at a CAGR of 14.5% during 2025 - 2030.

The Oncology Biosimilars market is gaining traction as healthcare systems worldwide seek cost-effective alternatives to branded biologics for treating cancer. Biosimilars offer comparable efficacy and safety to originator drugs at significantly lower costs, making them a preferred choice for healthcare providers and patients alike. As cancer incidence rates rise globally, the demand for affordable treatment options is fueling the growth of oncology biosimilars. Regulatory approvals and increasing physician awareness are further driving the adoption of biosimilars in oncology.

Monoclonal Antibodies Segment Is Largest Owing To Widespread Usage in Cancer Treatment

The monoclonal antibodies segment is the largest in the Oncology Biosimilars market, driven by their critical role in targeted cancer therapies. These biosimilars mimic the function of original monoclonal antibodies, which are designed to block cancer cell growth, modulate the immune system, or deliver toxic agents directly to cancer cells. Monoclonal antibody biosimilars are extensively used in the treatment of breast cancer, colorectal cancer, and blood cancers, among others, offering cost-effective solutions without compromising on therapeutic outcomes.

The increasing adoption of monoclonal antibody biosimilars is attributed to their proven efficacy, reduced treatment costs, and growing availability across key regions. As patents for originator drugs continue to expire, the launch of new biosimilars in this category is expected to sustain its dominance in the market.

Breast Cancer Segment Is Fastest Growing Owing To Rising Prevalence and Advancements in Treatment

The breast cancer segment is the fastest growing cancer type in the Oncology Biosimilars market. Breast cancer remains one of the most commonly diagnosed cancers globally, driving the demand for affordable and effective treatment options. Biosimilars targeting breast cancer, particularly those based on monoclonal antibodies such as trastuzumab, have seen rapid adoption due to their ability to reduce therapy costs while delivering comparable clinical outcomes.

The segment’s growth is further fueled by increasing awareness of early detection, expanding access to biosimilars in developing regions, and the introduction of new biosimilar products for breast cancer treatment. As healthcare systems aim to reduce the economic burden of cancer treatment, breast cancer biosimilars are poised for substantial growth.

Hospital Pharmacies Distribution Channel Is Largest Owing To High Patient Footfall

Hospital pharmacies represent the largest distribution channel in the Oncology Biosimilars market due to the high concentration of cancer treatment in hospital settings. Oncology biosimilars are frequently administered in hospitals, either as part of chemotherapy regimens or through specialized infusion centers. The complex nature of cancer treatments, which often require close monitoring by medical professionals, makes hospital pharmacies a preferred channel for biosimilar distribution.

The dominance of this segment is also attributed to the growing number of hospitals offering oncology services, along with increasing collaborations between biosimilar manufacturers and hospital networks. These partnerships facilitate the seamless integration of biosimilars into treatment protocols, ensuring wider availability to patients.

Hospitals End-Use Industry Is Largest Owing To Comprehensive Cancer Treatment Facilities

The hospitals segment is the largest end-use industry in the Oncology Biosimilars market, driven by their role as primary centers for cancer diagnosis, treatment, and management. Hospitals are equipped with advanced diagnostic and therapeutic infrastructure, making them the hub for administering complex oncology biosimilars, such as monoclonal antibodies and erythropoietin.

Additionally, the presence of multidisciplinary cancer care teams and specialized oncology departments in hospitals ensures that patients receive comprehensive treatment, further bolstering the demand for biosimilars in this setting. As hospitals increasingly adopt cost-effective treatment options to manage rising patient volumes, the demand for oncology biosimilars in this segment is expected to remain robust.

North America Region Is Largest Owing To Advanced Healthcare Infrastructure and High Adoption Rates

North America holds the largest share in the Oncology Biosimilars market, driven by the region’s advanced healthcare infrastructure, strong regulatory framework, and high adoption rates for biosimilars. The United States leads the market due to the increasing prevalence of cancer, favorable reimbursement policies, and the growing acceptance of biosimilars among healthcare providers. Additionally, the expiration of patents for key biologics and the introduction of new biosimilar products have further fueled market growth in this region.

The North American market benefits from the strong presence of major biosimilar manufacturers, active clinical trials, and a well-established distribution network. As healthcare providers seek to reduce treatment costs and improve patient access to oncology therapies, North America is expected to maintain its leadership position in the market.

Competitive Landscape and Key Players

The Oncology Biosimilars market is highly competitive, with leading companies focusing on innovation, regulatory compliance, and strategic partnerships to capture market share. Key players include Pfizer Inc., Amgen Inc., Sandoz (a Novartis division), Mylan N.V. (now Viatris), and Biocon Limited. These companies are actively expanding their biosimilar portfolios and investing in research and development to address the growing demand for oncology treatments.

The competitive landscape is marked by an increasing number of product launches, collaborations with healthcare providers, and efforts to expand access to biosimilars in emerging markets. As more biosimilars gain regulatory approval, competition in the Oncology Biosimilars market is expected to intensify, driving innovation and expanding treatment options for cancer patients worldwide.

Recent Developments:

• Amgen Inc. launched a biosimilar for colorectal and lung cancer treatment, focusing on affordability and accessibility.
• Pfizer Inc. received regulatory approval for a new monoclonal antibody biosimilar targeting breast cancer.
• Samsung Bioepis partnered with a global pharmaceutical company to expand its oncology biosimilar portfolio in emerging markets.
• Biocon Limited announced the successful completion of Phase III trials for its erythropoietin biosimilar targeting blood cancers.
• Dr. Reddy's Laboratories launched an oncology biosimilar in the European market, aiming to expand its footprint globally.

List of Leading Companies:

• Amgen Inc.
• Pfizer Inc.
• Novartis AG (Sandoz)
• Biocon Limited
• Mylan N.V. (Viatris)
• Teva Pharmaceutical Industries Ltd.
• Celltrion Healthcare
• Samsung Bioepis
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• Merck & Co., Inc.
• Fresenius Kabi
• STADA Arzneimittel AG
• Roche Holding AG
• Apotex Inc.

Report Scope: